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Copy number variants (CNVs) have been implicated in many complex diseases. We exam-
ined whether inherited CNVs were associated with overall survival among women with
invasive epithelial ovarian cancer. Germline DNA from 1,056 cases (494 deceased, aver-
age of 3.7 years follow-up) was interrogated with the Illumina 610 quad genome-wide
array containing, after quality control exclusions, 581,903 single nucleotide polymor-
phisms (SNPs) and 17,917 CNV probes. Comprehensive analysis capitalized upon the
strengths of three complementary approaches to CNV classification. First, to identify
small CNVs, single markers were evaluated and, where associated with survival, consec-
utive markers were combined. Two chromosomal regions were associated with survival
using this approach (14q31.3 rs2274736 p=1.59×10−6, p= 0.001; 22q13.31 rs2285164
p=4.01×10−5, p=0.009), but were not significant after multiple testing correction. Sec-
ond, to identify large CNVs, genome-wide segmentation was conducted to characterize
chromosomal gains and losses, and association with survival was evaluated by segment.
Four regions were associated with survival (1q21.3 loss p=0.005, 5p14.1 loss p=0.004,
9p23 loss p=0.002, and 15q22.31 gain p=0.002); however, again, after correcting for
multiple testing, no regions were statistically significant, and none were in common with
the single marker approach. Finally, to evaluate associations with general amounts of copy
number changes across the genome, we estimated CNV burden based on genome-wide
numbers of gains and losses; no associations with survival were observed (p>0.40).
Although CNVs that were not well-covered by the Illumina 610 quad array merit inves-
tigation, these data suggest no association between inherited CNVs and survival after
ovarian cancer.
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INTRODUCTION
Epithelial ovarian cancer is the fifth leading cause of cancer death
among women in the United States, accounting for 5% of cancer
deaths (Jemal et al., 2011). Though rare, most patients are diag-
nosed with advanced disease due to the non-specific nature of
early symptoms and lack of effective screening strategies. For the
approximate 75% of women diagnosed with stage III or IV disease,
the likelihood of long term disease-free survival ranges from 15 to
20% (Hoskins et al., 1992; McGuire et al., 2002; Barnholtz-Sloan
et al., 2003). As women may inherently vary in their ability to
eradicate disease or tolerate treatment, genetic association stud-
ies have sought to identify inherited variants related to overall
survival. In 2010, the first ovarian cancer genome-wide association
study (GWAS) to examine survival did not identify any repli-
cated survival-associated single nucleotide polymorphisms (SNPs;
Bolton et al., 2010).
Like SNPs, copy number variants (CNVs) occur commonly
in the genome and have been implicated in risk of complex dis-
eases including schizophrenia (Need et al., 2009), neuroblastoma
(Diskin et al., 2009), and prostate cancer (International Schizo-
phrenia Consortium, 2008; Liu et al., 2009). The size and frequency
of the detected CNV (deletions) from these studies varied, with
size of deletions ranging from intermediate (4 kb) to large (2 Mb).
CNVs are a priori more likely to have larger phenotypic effects
www.frontiersin.org August 2012 | Volume 3 | Article 142 | 1
Fridley et al. Copy number and cancer survival
than SNPs (Cooper et al., 2008), and they have been shown to
have adequate coverage on current SNP arrays, at least for large and
intermediate size CNVs (CNVs> 5 kb; McCarroll, 2008). There-
fore, to better understand inherited factors in ovarian cancer, we
used the Illumina 610 quad array to characterize CNVs and eval-
uate associations with survival among over 1,000 ovarian cancer
cases.
MATERIALS AND METHODS
STUDY POPULATION
Participants were from three previously described studies of inva-
sive epithelial ovarian cancer which enrolled cases from 2000 to
2008 from the upper Midwest [the Mayo Clinic Ovarian Can-
cer Study (MAY)], North Carolina [the North Carolina Ovarian
Cancer Study (NCO)], and the Tampa Bay, FL, USA area (the
Tampa Bay Ovarian Cancer Study, TBO; Permuth-Wey et al.,
2011). Research protocols were approved by institutional review
boards at each site, and all participants provided written informed
consent. Cases were followed for vital status through 2009 using
active contact, medical record review, and linkage to the National
Death Index.
GENOTYPING AND QUALITY CONTROL
DNA extracted from blood were genotyped at the Mayo Clinic
Genotyping Shared Resource Facility (Rochester, MN, USA) using
the Illumina Infinium 610 quad array as described previously
(Permuth-Wey et al., 2011). Genotyping was attempted for 4,169
samples including ineligible participants (population controls,
case without follow-up data, laboratory controls). Samples with
call rate<95%,ambiguous gender,unresolved identical genotypes,
self-reported non-Caucasian race, or less than 80% European
ancestry as predicted by structure (Pritchard et al., 2000) analysis
were excluded. This resulted in a sample size of 3,715, includ-
ing 1,056 for the current analysis. Markers on the X chromosome
or with call rate <80% were excluded, leaving 599,820 markers
(581,903 SNPs, 17,917 CNV probes) for CNV analysis.
NORMALIZATION OF INTENSITY DATA
Normalization of allelic intensities was completed similar to the
approach used by Barnes et al. (2008). Let Aij and Bij represent the
intensities of the two alleles for marker j measured on subject i.
First, systematic differences between the A and B intensities were
corrected using data for subjects with heterozygous genotype calls,
with correction factor for marker j equal to ψj =
( 1
K
) K∑
i=1
(
Aij
Bij
)
,
with K representing the number of subjects with heterozygous
genotype calls for marker j. This correction factor was then used
to compute the total intensity for marker j measured on subject i,
Iij = log2(Aij +ΨjBij).
Next, a two-step normalization procedure was completed to
remove plate and other experimental artifacts using quantile nor-
malization to produce similar intensity distributions for each
subject, followed by a median normalization for each marker by
plate. Using normalized intensity values, Zij = Iij − I¯i was com-
puted for each marker j measured on subject i, where I¯i is the
mean intensity for subject i computed over all the markers (mean
intensity for the subject).
PARAMETERIZATION OF CNVs
In order to comprehensively address the genetic architecture of
CNV association with ovarian cancer survival, CNVs were char-
acterized using three complementary approaches, as simulation
showed different approaches to have maximal statistical power
under varied genetic models (Breheny et al., 2012).
First, to identify associations with small, common CNVs, nor-
malized intensities at individual markers (Z ) were evaluated and,
where associated with survival (association methods described
below), results across neighboring genetic loci were combined
(Ionita-Laza et al., 2008). To combine results at consecutive mark-
ers, we performed fused lasso regression of −log10 (p-values;
Tibshirani et al., 2005), using the R package cghFLasso.1 In regions
of interest [smooth−log10 (p-value)>2], chromosomal segmen-
tation was completed using Partek® Discovery Suite™ (version
6.3) to more precisely define the associated CNV boundaries
(parameter settings: minimum of five markers, p-value thresh-
old= 0.001, signal to noise ratio= 0.3, region below=−0.3,
region above= 0.15).
Second, to identify associations with large, rare CNVs, genome-
wide segmentation was conducted to define chromosomal gains
and losses, and association with survival was evaluated by segment.
The number of copies present at each chromosomal segment for
each individual was estimated based on normalized intensities
(Z ; i.e., CNVs were “called”) using circular binary segmenta-
tion (CBS) methods of the R package DNAcopy with a three
marker minimum2 (Venkatraman and Olshen, 2007). The R pack-
age cghMCR was used to determine common CNV regions and
combine adjacent regions3 (Aguirre et al., 2004; lower thresh-
old= 3rd percentile, upper threshold= 97th percentile, required
recurrence= five). At every segment for which copy number was
variable, association testing was conducted (association methods
described below).
Finally, because markers or regions may not individually pre-
dict ovarian cancer survival, we also evaluated the general amount
of copy number changes across the genome (i.e., CNV burden;
Kathiresan et al., 2009). Genome-wide CNV burden for each par-
ticipant was defined based on CBS of normalized intensities (Z ) in
three ways: the total number of gains or losses, the total number of
gains, and the total number of losses. Association testing was then
conducted for these three values (association methods described
below). However, a limitation of this burden analysis approach
is that the sizes of the CNVs are not taken into account during
the analysis, as estimation of CNV breakpoints (and sizes) based
GWAS data is difficult.
ASSOCIATION TESTING
Association with overall survival was completed using Cox pro-
portional hazards regression, accounting for left truncation, with
estimation of hazard ratios (HRs) and 95% confidence intervals
(CIs; Therneau and Grambsch, 2000). Time at risk was defined
as date of diagnosis to death with censoring at last follow-up.
As described above, the CNV variable of interest was either the
1http://cran.r-project.org/web/packages/cghFLasso/
2http://www.bioconductor.org/packages/release/bioc/html/DNAcopy.html
3http://www.bioconductor.org/packages/release/bioc/html/cghMCR.html
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normalized intensity at each marker (Z ), the number of copies of
certain chromosomal sections, or one of three measures of CNV
burden. To control for population stratification, the first principal
component from eigen-analysis of non-Hispanic white partici-
pants (Price et al., 2006; Permuth-Wey et al., 2011) was included
as a covariate along with study site and age at diagnosis.
RESULTS
With an average 3.7 years of follow-up, 494 recurrences or
deaths were observed among 1,056 successfully genotyped invasive
epithelial ovarian cancer cases with follow-up for disease outcome.
As shown in Table 1, 62% of cases were of serous histology, 71%
were diagnosed at advanced stage, and the majority of subjects
were enrolled within 4 months of diagnosis.
Analysis of individual normalized marker intensities followed
by combination of results across multiple consecutive markers is
the most powerful approach for the detection of associations with
small, common CNVs. Two regions showed suggestive associa-
tion with ovarian cancer survival at multiple markers [smoothed
−log10 (p) >2]. On 14q31.3 (379 kb, 63 markers) a smoothed
p= 0.001 was observed suggesting a modest regional associa-
tion with survival. As shown in Figure 1A, normalized inten-
sities at rs2274736, a non-synonymous SNP in PTPN21, alone
appeared to be driving the regional association. In fact, this SNP
was the most significant single marker in genome-wide analysis
(p= 1.6× 10−6); note, however that it did not reach traditional
genome-wide significance. Genomic segmentation in 14q31.3 was
then done to identify specific gains or loss among study partici-
pants; however, only two samples were detected with gains and 18
samples with losses. Due to the lack of called CNVs in this region,
further analysis was not carried out in 14q31.3.
A second region with suggestive association with cancer sur-
vival at multiple markers was on 22q13.31 centered at rs2285164
(smoothed p= 0.009, 397 kb, 160 markers; Figure 1B). Genomic
segmentation of 22q13 was then computed to identify specific
gains or loss among study participants (Inc, 2008), where 35
showed gain and 154 showed loss. Association testing of gain
(N = 35), normal (N = 867), or loss (N = 154) with survival did
not reveal association (p= 0.29 for two degrees of freedom test;
treating CNV as a categorical variable; p= 0.67 for one degree of
freedom trend test treating CVN as a continuous variable). Thus,
even though a signal was observed for association from the single
marker analysis on 22q13, CNV calling, and subsequent analysis
of this region showed no association between CNV and overall
survival (Figure 2).
An inverse approach analyzing pre-defined regions of CNV
change is most powerful for the detection of associations with
large, rare CNVs. Genome-wide CBS identified 564 regions with
variable copy number among the study population, including
78 regions with gain and 486 regions with loss (available upon
Table 1 | Clinical characteristics of invasive epithelial ovarian cancer cases.
MAY (N=352) NCO (N=492) TBO (N=212) Total (N=1,056)
N (%) N (%) N (%) N (%)
Deceased 171 (49) 229 (47) 94 (44) 494 (47)
STAGE (FIGO)
I 67 (19) 125 (25) 36 (17) 228 (22)
II 26 (7) 36 (7) 16 (8) 78 (7)
III 199 (57) 314 (64) 139 (66) 652 (62)
IV 56 (16) 15 (3) 21 (10) 92 (9)
Missing 4 (1) 2 (0) 0 (0) 6 (1)
GRADE
I 13 (4) 65 (13) 15 (7) 93 (9)
II 45 (13) 137 (28) 38 (18) 220 (21)
III 288 (82) 278 (57) 159 (75) 725 (69)
Missing 6 (2) 12 (2) 0 (0) 18 (2)
HISTOLOGY
Serous 221 (63) 293 (60) 138 (65) 652 (62)
Endometrioid 71 (20) 81 (16) 27 (13) 179 (17)
Clear Cell 24 (7) 58 (12) 11 (5) 93 (9)
Mucinous 11 (3) 20 (4) 12 (6) 43 (4)
Mixed/Other 25 (7) 40 (8) 19 (9) 84 (8)
Missing 0 (0) 0 (0) 5 (2) 5 (0)
Mean (range) Mean (range) Mean (range) Mean (range)
Age at diagnosis 61.4 (28–91) 57.1 (22–74) 61.5 (26–93) 59.4 (22–93)
Days from diagnosis to enrollment 35.5 (0–835) 102.7 (5–1,178) 99.3 (0–947) 79.6 (0–1,178)
Years from diagnosis to last follow-up 3.3 (0.02–9.5) 4.6 (0.5–10.0) 2.5 (0.02–8.3) 3.7 (0.02–10.0)
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FIGURE 1 | Association between ovarian cancer survival and
normalized intensities at individual markers (black dots)
and smoothed regional association (red line) in (A) 14q31
and (B) 22q13; Genomic Build 36. Analysis adjusted for study
site, age at diagnosis, and first two population structure principal
components.
request). Association testing of these regions revealed 14 regions
with p-values <0.05, including one region of gain and 13 regions
of loss (Table 2). Results at the most statistically significant
regions (p= 0.002) suggested that loss of a region on 9p23 was
associated with poorer survival (HR 1.44, 95% CI 1.14–1.81)
as was gain of a region on 15q22.31 (HR 1.34, 95% CI 1.11–
1.61). However, no region was statistically significant after cor-
rection for multiple testing using a Bonferroni procedure (564
tests).
Because the overall amount of variation from normal copy
number across the genome (CNV burden) may contribute to dis-
ease, CNV burden for each case was estimated as summarized in
Table 3. There was no association between survival and number
of gains (p= 0.42), number of losses (p= 0.94), or total number
of gains and losses (p= 0.84).
DISCUSSION
Single nucleotide polymorphisms GWASs have yielded great
insights into the etiology several complex diseases including ovar-
ian cancer4 (Song et al., 2009; Bolton et al., 2010). However,
germline variation related to disease outcome has been more elu-
sive, with the possible exception of acute lymphocytic leukemia.5
With much unexplained variation in ovarian cancer outcome,
4http://www.nature.com/ng/journal/v42/n10/full/ng.668.html
5http://www.nature.com/ng/journal/v43/n3/full/ng.763.html
Frontiers in Genetics | Cancer Genetics August 2012 | Volume 3 | Article 142 | 4
Fridley et al. Copy number and cancer survival
investigation of additional inherited factors remains warranted.
Here, in the first germline ovarian cancer CNV analysis, we have
harnessed CNV data gleaned from dense genome-wide SNP geno-
typing in order to address the hypothesis that copy number varia-
tion is associated with survival. With over 1,000 cases (almost 500
deaths) representing three study populations, results were largely
null suggesting no strong associations between small CNVs, large
CNVs, or general CNV burden and ovarian cancer outcome.
There are numerous strengths to this study. First, the Illu-
mina Infinium 610 quad array included markers in known
FIGURE 2 | Kaplan–Meier plot of the 22q13 CNV association with
ovarian cancer survival.The different lines represent the survival curve for
subjects with a “loss,” “gain,” or “normal” for the genomic segment.
regions according to the Toronto Database of Genomic Varia-
tion with approximately 38 markers per CNV region, markers
in the “unSNPable” genome, markers in novel CNV regions, and
intensity-only probes resulting in an average (median) coverage
of 93% (100%) for white non-Hispanic populations.6 Second, our
analysis leveraged a large sample size providing power to detect a
HR of 1.75 for a CNV with frequency of 20% at a significance level
of 10−5 (or HR= 2.00 at p< 10−7). Third, based on the available
SNP data, assessment, and correction for possible population strat-
ification to eliminate spurious associations due to confounding
was performed. Fourth, extensive normalization of the intensity
data from the SNP array was completed in order to produce reliable
CNV calls. Finally, three complementary approaches for assess-
ment and testing association between CNVs and ovarian cancer
survival were utilized.
However, we cannot rule out more modest associations
(HR< 2.0) between CNVs and ovarian cancer survival, and we
cannot rule out associations with very small CNVs (<10 kb) which
were not covered in Infinium 610 quad array. Despite this study
being the largest of its kind to determine germline CNVs associ-
ated survival, the sample size was still relatively small and restricted
to subjects of European ancestry. Finally, it is possible that CNVs
exhibit survival effects only in the context of certain chemother-
apeutic regimens or only among certain subtypes; these analyses
are important and may reveal associations masked in the current
analysis.
In conclusion, this study did not detect any CNVs associated
with ovarian cancer survival using the data from the Infinium
610 quad array in three populations. Future research may reveal
whether germline CNVs play a role in ovarian cancer etiology or
in outcome within certain clinical contexts.
6www.illumina.com
Table 2 | Association between CNV region and ovarian cancer survival (p <0.05).
Chr Location (bp) N Gain N Normal N Loss HR (95% CI) p-Value
1p31.1 72,538,673–72,549,855 0 992 64 1.52 (1.08–2.15) 0.017
1q21.3 151,026,302–151,033,105 0 947 109 1.46 (1.12–1.89) 0.005
4p15.31 19,130,834–19,131,054 0 994 62 1.48 (1.03–2.11) 0.032
5p14.1 27,462,485–27,462,654 0 975 81 1.54 (1.15–2.07) 0.004
6p21.33 30,017,499–30,017,538 0 1001 55 1.44 (1.01–2.06) 0.043
6p21.32 32,756,221–32,758,787 0 996 60 1.44 (1.01–2.05) 0.045
6q24.1 141,045,394–141,083,022 0 969 87 1.45 (1.07–1.94) 0.015
7q11.21 65,415,344–65,417,964 0 948 108 1.35 (1.03–1.76) 0.031
7q31.1 109,237,359–109,238,466 0 940 116 1.34 (1.04–1.74) 0.026
8q13.3 70,795,078–70,795,945 0 893 163 0.75 (0.57–0.97) 0.031
9p23 11,398,647–11,398,865 0 906 150 1.44 (1.14–1.81) 0.002
12q12 38,668,966–38,671,005 0 969 87 1.43 (1.07–1.91) 0.015
12q23.1 95,745,302–95,745,411 0 963 93 0.62 (0.43–0.90) 0.013
15q22.31 63,701,811–63,710,800 339 717 0 1.34 (1.11–1.61) 0.002
HR, hazard ratio; CI, confidence interval adjusted for study site, age at diagnosis, and first two population structure principal components.
The start and end point based on the minimum common region determined from R package cghMCR (Aguirre et al., 2004), genomic build 36; normal number of
copies is the reference group.
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Table 3 | Mean genome-wide CNV burden by vital status and association with overall survival.
Alive (N=562) Deceased (N=494) HR (95% CI) p-Value
Mean (SD) Mean (SD)
N Losses 46.96 (22.47) 47.98 (20.76) 0.9998 (0.9958–1.0039) 0.94
N Gains 11.85 (6.75) 12.51 (6.85) 1.0051 (0.9926–1.0179) 0.42
Total N Gains and Loses 58.80 (23.35) 60.49 (21.44) 1.0000 (0.9997–1.0002) 0.84
p-Value, hazard ratio (HR), and confidence intervals (CI) from hazards regression adjusted for study site, age at diagnosis, and first two population structure principal
components.
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